Uncategorized

Amgen’s Tavneos troubles continue as NEJM retracts pivotal publication

Published

on

Earlier this year, Amgen refused the FDA’s request to withdraw Tavneos from the market. Now, two researchers who participated in the original study to support the drug’s approval claim they did not know the primary endpoint was readjudicated after the study was unblinded.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version